Verapamil, a phenylalkylamine analog, is used to treat high blood pressure and angina. This analytical reference standard is applicable for use as starting material in calibrators or controls for verapamil testing methods by LC-MS/MS or GC-MS. A calcium channel blocker, verapamil is sold under trade names Calan® and Covera-HS®.
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Calan is a registered trademark of G.D. Searle & Co.
Covera-HS is a registered trademark of G.D. Searle, LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Biochimica et biophysica acta, 1831(4), 683-690 (2013-01-12)
Although human MDR1 and MDR3 share 86% similarity in their amino acid sequences and are predicted to share conserved domains for drug recognition, their physiological transport substrates are quite different: MDR1 transports xenobiotics and confers multidrug resistance, while MDR3 exports
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 437-446 (2013-01-30)
Through PET imaging, our laboratory has studied the dynamic biodistribution of (11)C-verapamil, a P-gp substrate, in the nonhuman primate Macaca nemestrina. To gain detailed insight into the kinetics of verapamil transport across the blood-brain barrier (BBB) and the blood-placental barrier
In this paper we give a method of integrated treatment for cancer and drug-induced complications in the process of cancer therapy through dual-drug delivery system (DDDS). Two hydrophilic drugs, doxorubicin (an antitumor drug) and verapamil (an antiangiocardiopathy drug) combined preliminarily
Ugeskrift for laeger, 175(1-2), 54-55 (2013-01-12)
Verapamil administered intravenously is recommended as a first-line therapy in patients with supraventricular tachycardia. However, these patients may suffer from tachycardia-induced heart failure and particular caution is needed before prescription of verapamil in these cases. We present a case of
We sought to identify novel pharmacogenetic markers associated with cardiovascular outcomes in patients with hypertension on antihypertensive therapy. We genotyped a 1:4 case:control cohort (n=1345) on the Illumina HumanCVD Beadchip from the INternational VErapamil SR-Trandolapril STudy (INVEST), where participants were
